Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
NCT ID: NCT06362941
Last Updated: 2025-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
250 participants
INTERVENTIONAL
2024-05-20
2025-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females
NCT06376409
Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
NCT05332743
Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females
NCT03052413
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
NCT06146166
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
NCT05339958
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nutrafol Hair Growth Supplement
5 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.
Nutrafol Women's Hair Growth Supplemnt
Hair growth supplement for women ages 18 - 44.
Nutrafol Women's Balance Hair Growth Supplement
Hair growth supplement for women ages 45 - 70.
Nutrafol Women's Vegan Hair Growth Supplement
Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.
Nutrafol Women's Postpartum Hair Growth Supplement
Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
Nutrafol Men's Hair Growth Supplement
Hair growth supplement for men ages 25 - 50.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutrafol Women's Hair Growth Supplemnt
Hair growth supplement for women ages 18 - 44.
Nutrafol Women's Balance Hair Growth Supplement
Hair growth supplement for women ages 45 - 70.
Nutrafol Women's Vegan Hair Growth Supplement
Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.
Nutrafol Women's Postpartum Hair Growth Supplement
Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
Nutrafol Men's Hair Growth Supplement
Hair growth supplement for men ages 25 - 50.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subjects must meet the age characteristics based on their supplement group assignment.
3. Subjects are Fitzpatrick Skin Types I to VI.
4. Subjects must be in good general health.
5. Subjects must be classified with thinning hair by the study dermatologist.
6. Willing to maintain the same hair length, hairstyle, and coloring practices for the duration of the study. Subjects who have color-treated hair must have the color treatment performed at the same time interval prior to each visit.
7. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
8. Willing and able to adhere to the same dietary lifestyles for the duration of the study
9. Subjects must express willingness to cooperate with the investigator and comply to study requirements.
10. Subjects must demonstrate the ability to read and understand all the items in the informed consent document.
11. Subjects must agree not to use any other hair supplements or start a new vitamin supplement during the study.
12. Subject has signed an Informed Consent Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
13. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.
Exclusion Criteria
2. Subjects possessing signs of severe female or male pattern hair loss or alopecia (including androgenetic and traction alopecia) as determined by the study dermatologist.
3. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
4. Subjects who are not willing to use only the assigned oral study supplement and no new oral supplements during the study.
5. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study product.
6. Subjects, who are pregnant, breast feeding, or planning a pregnancy.
7. Subjects with clinically significant unstable medical disorders.
8. Subjects who are unwilling or unable to comply with the requirements of the protocol.
9. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and/or follow the requirements of the study.
10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.
11. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
12. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
13. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
14. hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
15. History of burning, flaking, itching, and stinging of the scalp.
16. Utilization of low-level lasers for hair growth in the last three months.
17. Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage \>20 cigarettes/day.
18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutraceutical Wellness Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Consulting Services
High Point, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NW-HGN-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.